Healthcare provider profile · identity verified

Corey Andrew Jones, DO

Allopathic & Osteopathic Physicians|Family Medicine · GREELEY, CO · NPI 1790309318

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Corey Andrew Jones, DO received $24.32 in general payments during 2025 across 1 reported records.

Edwards Lifesciences Corporation accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$24.32

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Edwards Lifesciences Corporation Unresolved — no canonical attribution shown $24.32100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$24.321

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
SAPIEN 3 Ultra RESILIA
Normalized: sapien 3 ultra resilia
Device Edwards Lifesciences Corporation $24.32 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium25597
Levothyroxine SodiumLevothyroxine Sodium16152
LisinoprilLisinopril15460
Losartan PotassiumLosartan Potassium13750
OmeprazoleOmeprazole11341
Metformin Hcl ErMetformin Hcl10934
Albuterol Sulfate HfaAlbuterol Sulfate10337
Tamsulosin HclTamsulosin Hcl10038
GabapentinGabapentin9837
Amlodipine BesylateAmlodipine Besylate8632
HydrochlorothiazideHydrochlorothiazide7428
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen7417
Rosuvastatin CalciumRosuvastatin Calcium6628
Metformin HclMetformin Hcl6321
Pantoprazole SodiumPantoprazole Sodium6027
SimvastatinSimvastatin6022
FurosemideFurosemide5328
Fluticasone PropionateFluticasone Propionate4928
Metoprolol SuccinateMetoprolol Succinate4918
FamotidineFamotidine4817
Potassium ChloridePotassium Chloride4614
Tramadol HclTramadol Hcl4525
AllopurinolAllopurinol4415
MeloxicamMeloxicam3615
PrednisonePrednisone3528
Sertraline HclSertraline Hcl3512
Metoprolol TartrateMetoprolol Tartrate3413
TrulicityDulaglutide33suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl3221
Fluoxetine HclFluoxetine Hcl30suppressed
Glipizide ErGlipizide28suppressed
Oxycodone HclOxycodone Hcl28suppressed
Trazodone HclTrazodone Hcl2812
EliquisApixaban27suppressed
Diclofenac SodiumDiclofenac Sodium2622
JardianceEmpagliflozin26suppressed
Montelukast SodiumMontelukast Sodium26suppressed
ClonazepamClonazepam25suppressed
Doxycycline HyclateDoxycycline Hyclate2522
SpironolactoneSpironolactone25suppressed
Amitriptyline HclAmitriptyline Hcl24suppressed
Olmesartan MedoxomilOlmesartan Medoxomil24suppressed
Hydroxyzine PamoateHydroxyzine Pamoate23suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav2221
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide22suppressed
Oxybutynin Chloride ErOxybutynin Chloride22suppressed
CephalexinCephalexin2119
Escitalopram OxalateEscitalopram Oxalate21suppressed
Triamcinolone AcetonideTriamcinolone Acetonide2116
Bupropion XlBupropion Hcl20suppressed
SynthroidLevothyroxine Sodium20suppressed
AlprazolamAlprazolam18suppressed
Duloxetine HclDuloxetine Hcl18suppressed
CarvedilolCarvedilol17suppressed
EzetimibeEzetimibe17suppressed
Pravastatin SodiumPravastatin Sodium17suppressed
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17suppressed
Venlafaxine Hcl ErVenlafaxine Hcl17suppressed
EszopicloneEszopiclone16suppressed
Ondansetron HclOndansetron Hcl1612
ValacyclovirValacyclovir Hcl16suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15suppressed
Pioglitazone HclPioglitazone Hcl15suppressed
Warfarin SodiumWarfarin Sodium15suppressed
AmoxicillinAmoxicillin14suppressed
FinasterideFinasteride14suppressed
GlipizideGlipizide14suppressed
GlyburideGlyburide14suppressed
Hydroxyzine HclHydroxyzine Hcl14suppressed
JanuviaSitagliptin Phosphate14suppressed
MethocarbamolMethocarbamol14suppressed
OzempicSemaglutide14suppressed
PregabalinPregabalin14suppressed
SymbicortBudesonide/Formoterol Fumarate14suppressed
AzithromycinAzithromycin13suppressed
Citalopram HbrCitalopram Hydrobromide13suppressed
Bupropion Hcl SrBupropion Hcl12suppressed
ForteoTeriparatide12suppressed
LorazepamLorazepam12suppressed
Acetaminophen-CodeineAcetaminophen With Codeine11suppressed
CilostazolCilostazol11suppressed
LovastatinLovastatin11suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst1111
Propranolol HclPropranolol Hcl11suppressed
Sumatriptan SuccinateSumatriptan Succinate11suppressed
TopiramateTopiramate11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $24.32 · 1 records Edwards Lifesciences Corporation SAPIEN 3 Ultra RESILIA
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error